Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 10/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27111193 | 0.83 | ACSS2 (0.36) | AGTR1AGTR2PPARGACSS2MEN1 | |
| SCHEMBL27153108 | 0.78 | ACSS2 (0.47) | AGTR1AGTR2PPARGACSS2 | |
| SCHEMBL22992635 | 0.75 | DRD2 (0.45) | PPARGACSS2MEN1KMT2A | |
| SCHEMBL25373335 | 0.75 | ACSS2 (0.42) | AGTR1AGTR2PPARGACSS2HCAR3 | |
| SCHEMBL25373333 | 0.75 | ACSS2 (0.42) | AGTR1AGTR2PPARGACSS2HCAR3 | |
| SCHEMBL29945891 | 0.74 | DRD2 (0.41) | ACSS2GLP1R | |
| SCHEMBL29491249 | 0.73 | AGTR1 (0.43) | AGTR1AGTR2PPARGACSS2MEN1 | |
| SCHEMBL22009940 | 0.71 | GLP1R (0.51) | AGTR1AGTR2PPARGACSS2MEN1 | |
| SCHEMBL6168561 | 0.70 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL30233144 | 0.69 | GLP1R (0.50) | AGTR1AGTR2PPARGACSS2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | AGTR1 96/4885AGTR2 163/4885PPARG 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.